• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

March 11, 2011

View Archived Issues

Exelixis Adds $165M to Cancer Drug Development

A $165 million underwriting agreement may be the prescription Exelixis Inc. needs to get its cancer candidate, cabozantinib, through clinical development. Read More

BioCryst Monetizes Peramivir Payments in $30M Financing

BioCryst Pharmaceuticals Inc. took an inventive tack to raise $30 million this week by monetizing payments from licensee Shionogi & Co. Ltd., of Osaka, Japan, for peramivir (Rapiacta), a neuraminidase inhibitor for the treatment of influenza. Read More

Lucentis' Phase III Data Show DME Improvements

Genentech reported that data from the first of two pivotal Phase III studies of Lucentis (ranibizumab injection) in diabetic macular edema (DME) showed "rapid and sustained improvement in vision" compared to a placebo injection. Read More

Stock Movers

Read More

Benlysta Launching with One Year Supply, 150 Sales People

Now that there's a new approved systemic lupus erythematosus (SLE) therapy for the first time in 56 years, patients and rheumatologists will only have to bide their time for about two more weeks before they can get Benlysta. Read More

Esai Partnership a Ringing Endorsement of EZH2

Epizyme Inc. views its potential $206 million new partnership agreement with Eisai Co. Ltd. as an endorsement of its research and development efforts in EZH2, and as a complement to its recent deal with GlaxoSmithKline plc within its overall business strategy. Read More

Other News To Note

MediGene AG, of Martinsreid, Germany, signed an exclusive license and supply agreement with Will-Pharma for commercialization and marketing of Veregen ointment for genital warts in Belgium, the Netherlands, and Luxembourg. It has existing agreements covering the U.S., other parts of Europe, Latin America and Asia. It will continue to pursue a global licensing strategy for the drug. Read More

Clinic Roundup

Vertex Pharmaceuticals Inc., of Cambridge, Mass., reported results from a Phase II study of VX-765, a caspase-1 inhibitor, in 60 patients with treatment-resistant epilepsy, with data showing a similar safety profile for VX-765 as compared to placebo, the primary endpoint. Secondary endpoint data showed that 13 percent of patients in the treatment arm showed a 50 percent or greater reduction in seizure frequency vs. 0 percent in the placebo arm, and 19 percent of patients on VX-765 were seizure-free in the last two weeks of treatment vs. 9 percent on placebo. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Vertex Pharmaceuticals discovers new PKD1 correctors

    BioWorld Science
    Vertex Pharmaceuticals Inc. has described polycystin-1 (PKD1) (mutant) correctors reported to be useful for the treatment of autosomal dominant polycystic kidney...
  • Ozempic pen and packaging

    EMA warns Ozempic linked to ‘very rare’ side effect

    BioWorld
    The EMA’s safety committee has issued a warning that the GLP-1 receptor agonist Ozempic (semaglutide, Novo Nordisk A/S) can cause an acute eye condition in which...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe